Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Changes to DNA on-off switches affect cells' ability to repair breaks, respond to chemotherapy

04.02.2013
Double-strand breaks in DNA happen every time a cell divides and replicates.

Depending on the type of cell, that can be pretty often. Many proteins are involved in everyday DNA repair, but if they are mutated, the repair system breaks down and cancer can occur. Cells have two complicated ways to repair these breaks, which can affect the stability of the entire genome.

Roger A. Greenberg, M.D., Ph.D., associate investigator, Abramson Family Cancer Research Institute and associate professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania, together with postdoctoral researcher Jiangbo Tang Ph.D. and colleagues, found a key determinant in the balance between two proteins, BRCA1 and 53BP1, in the DNA repair machinery. Breast and ovarian cancer are associated with a breakdown in the repair systems involving these proteins. Their findings appear in the latest online issue of Nature Structural & Molecular Biology.

The two proteins, BRCA1 and 53BP1, control which of two cell-repair mechanisms will be used: homologous recombination or non-homologous end-joining, technically speaking. This competition has proven to be a key factor in determining whether a cell becomes cancer prone as well as how a cancer cell will respond to chemotherapy.

The key step of the balance is acetylation, the chemical process of adding a compound called an acetyl group to other cellular molecules.

The researchers asked what cell signals determine whether BRCA or 53BP1 predominates at a DNA break site.

DNA in the nucleus is tightly packed around proteins called histones. Acetylation at a specific spot on histone H4 determines the answer. If H4 is acetylated at a specific location, then 53BP1 binding near the broken DNA region is strongly reduced. This leaves BRCA1 free to do the work, kicking in the homologous recombination tool to repair the break.

On the other hand, if acetylation is reduced, 53BP1 outcompetes BRCA1 at a break and the non-homologous end-joining tool repairs the break.

This mechanism can help explain resistance to a promising chemotherapy called PARP inhibition seen in patients and mouse models with BRCA1 mutations. Work from several other research teams surprisingly has shown that if neither BRCA nor 53BP1 are available, then the homologous recombination system goes into action even in the absence of BRCA1 and BRCA1 mutant cancer cells become resistant to PARP inhibitors.

Because of this, Greenberg says, there are some possible applications for making PARP chemotherapy more sensitive: "If you could inhibit specific acetylation events, then a patient's response to PARP inhibitors might be enhanced by hyperactivating 53BP1 binding to breaks in the context of BRCA1 deficient cancers. What's more, measuring the levels of acetylation at H4 might predict how responsive an individual is to PARP inhibitors."

"The story didn't fall into place the way we thought it would," says Greenberg. "We didn't realize that it was a combination of two epigenetic marks that drives the repair system. However, we were able to show that 53BP1 doesn't bind well to regions of histone H4 that are acetylated at a specific location on H4. Collaboration with Georges Mer, a structural biologist at the Mayo Clinic, helped provide the molecular basis for these findings. We think there will be further complexity to this regulation, creating the possibility for the discovery of additional mechanisms that regulate DNA repair pathways and response to therapy and potential new targets for diagnosis and therapy."

Co-authors are Nam Woo Cho, Erica M. Manion, Niraj M. Shanbhag, all from Penn, and Gaofeng Cui, Maria Victoria Botuyan, and Georges Mer, from the Department of Biochemistry and Molecular Biology, Mayo Clinic.

The research was supported by the National Cancer Institute (1R01CA138835-01, 1R01CA132878, P50CA116201), a Research Scholar Grant from the American Cancer Society, a DOD Breast Cancer Idea Award, a UPENN-FCCC SPORE Pilot Grant, and funds from the Abramson Family Cancer Research Institute and Basser Research Center for BRCA.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Life Sciences:

nachricht The first genome of a coral reef fish
29.09.2016 | King Abdullah University of Science and Technology

nachricht New switch decides between genome repair and death of cells
27.09.2016 | University of Cologne - Universität zu Köln

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Experimentalphysik - Protonenstrahlung nach explosiver Vorarbeit

LMU-Physiker haben mit Nanopartikeln und Laserlicht Protonenstrahlung produziert. Sie könnte künftig neue Wege in der Strahlungsmedizin eröffnen und bei der Tumorbekämpfung helfen.

Stark gebündeltes Licht entwickelt eine enorme Kraft. Ein Team um Professor Jörg Schreiber vom Lehrstuhl für Experimentalphysik - Medizinische Physik der LMU...

Im Focus: Der perfekte Sonnensturm

Ein geomagnetischer Sturm hat sich als Glücksfall für die Wissenschaft erwiesen. Jahrzehnte rätselte die Forschung, wie hoch energetische Partikel, die auf die Magnetosphäre der Erde treffen, wieder verschwinden. Jetzt hat Yuri Shprits vom Deutschen GeoForschungsZentrum GFZ und der Universität Potsdam mit einem internationalen Team eine Erklärung gefunden: Entscheidend für den Verlust an Teilchen ist, wie schnell die Partikel sind. Shprits: „Das hilft uns auch, Prozesse auf der Sonne, auf anderen Planeten und sogar in fernen Galaxien zu verstehen.“ Er fügt hinzu: „Die Studie wird uns überdies helfen, das ‚Weltraumwetter‘ besser vorherzusagen und damit wertvolle Satelliten zu schützen.“

Ein geomagnetischer Sturm am 17. Januar 2013 hat sich als Glücksfall für die Wissenschaft erwiesen. Der Sonnensturm ermöglichte einzigartige Beobachtungen, die...

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: Neuer Schalter entscheidet zwischen Reparatur und Zelltod

Eine der wichtigsten Entscheidungen, die eine Zelle zu treffen hat, ist eine Frage von Leben und Tod: kann ein Schaden repariert werden oder ist es sinnvoller zellulären Selbstmord zu begehen um weitere Schädigung zu verhindern? In einer Kaskade eines bisher wenig verstandenen Signalweges konnten Forscher des Exzellenzclusters für Alternsforschung CECAD an der Universität zu Köln ein Protein identifizieren (UFD-2), das eine Schlüsselrolle in dem Prozess einnimmt. Die Ergebnisse wurden in der Fachzeitschrift Nature Structural & Molecular Biology veröffentlicht.

Die genetische Information einer jeden Zelle liegt in ihrer Sequenz der DNA-Doppelhelix. Doppelstrangbrüche der DNA, die durch Strahlung hervorgerufen werden...

Im Focus: Forscher entwickeln quantenphotonischen Schaltkreis mit elektrischer Lichtquelle

Optische Quantenrechner könnten die Computertechnologie revolutionieren. Forschern um Wolfram Pernice von der Westfälischen Wilhelms-Universität Münster sowie Ralph Krupke, Manfred Kappes und Carsten Rockstuhl vom Karlsruher Institut für Technologie ist es nun gelungen, einen quantenoptischen Versuchsaufbau auf einem Chip zu platzieren. Damit haben sie eine Voraussetzung erfüllt, um photonische Schaltkreise für optische Quantencomputer nutzbar machen zu können.

Ob für eine abhörsichere Datenverschlüsselung, die ultraschnelle Berechnung riesiger Datenmengen oder die sogenannte Quantensimulation, mit der hochkomplexe...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Das Heidelberg Laureate Forum: Eine Veranstaltung mit Zukunft

29.09.2016 | Veranstaltungen

Wissenschaftsjahr Meere und Ozeane - Oktober 2016

29.09.2016 | Veranstaltungen

EEHE 2017 – Strom statt Benzin. Experten diskutieren die Umsetzung neuester Fahrzeugkonzepte. Call vor Papers endet am 31.10.2016!

28.09.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Schwerste Atome im Rampenlicht

29.09.2016 | Physik Astronomie

Zelluläres Kräftemessen

29.09.2016 | Interdisziplinäre Forschung

K 2016: Von OLED-Verkapselung bis Plagiatschutz

29.09.2016 | Messenachrichten